PIK3CA and breast cancer: The SAFIR02-BREAST and SAFIR-PI3K phase II randomized studies enrolled 1462 patients with metastatic HER2− BC and evaluated the maintenance with targeted therapies (including alpelisib with fulvestrant), guided by genomics versus chemotherapy.